MDX: Promising Treatment for Inattentive ADHD?
There may be hope on the horizon for those diagnosed with Predominantly Inattentive ADHD. A drug called Metadoxine Extended Release (MDX) — developed by Alcobra, a biopharmaceutical company focused on developing new medications to help patients with cognitive disorders — provided significant benefit for adults with inattentive ADHD in a Phase IIb study. The results will be […]
There may be hope on the horizon for those diagnosed with Predominantly Inattentive ADHD. A drug called Metadoxine Extended Release (MDX) — developed by Alcobra, a biopharmaceutical company focused on developing new medications to help patients with cognitive disorders — provided significant benefit for adults with inattentive ADHD in a Phase IIb study.
The results will be presented to the American Psychological Association on May 10.
In the randomized double-blind study of 36 adult patients, aged 18 to 55 years old, adults who were given 1400 mg. of Metadoxine did better on attention and cognition scores than those given 700 mg. of the same medication or placebo.
The drug was as well tolerated as the placebo. Side effects noted were moderate headache and fatigue.
Based on these results and the successful outcome of a prior Phase II placebo-controlled study of MDX, Alcobra is moving forward with a Phase III trial in adults with ADHD. The study is expected to be completed in the second half of 2014.
